Center for Mucosal Immunobiology and Rheumatic Disease Pathogenesis Administrative Core

行政核心将支持科罗拉多大学(CU)NIAMS的43名成员P30 风湿病研究资源中心(RDRRC)在研究实施的各个方面， 管理、执行、合规和报告。这一管理核心的总体目标是 通过为成员提供与中心沟通的直接线路，增强和扩大研究基础， 有组织地访问研究资源核心咨询和会员折扣，并参与所有 提案中概述的计划。迈克尔·霍勒斯博士将担任行政核心主任，以及 克里斯蒂·库恩博士将担任副主任一职。中心管理员林赛·麦克布莱德女士， 将管理财务方面，Becky Alberti-Powell女士将作为沟通和 外展。充实计划将由霍勒斯博士领导，在整个职业生涯早期都是重点 发展。作为这一计划的一部分，一项试点和可行性拨款计划将由罗伯特·富尔布里奇博士监督， Kristi Kuhn博士将把一个具体的目标和拨款提交前审查计划整合到现有的 强大的CU CTSA支持的项目，以及客座教授和新技术评论系列 将被组织和管理。凯文·迪恩博士将领导社交媒体和传播项目。一个 创新的患者影响计划，包括生物标记物和治疗开发组件 将与CU创新中心整合，将由Holers博士和Ashley Frazer-Abel博士共同指导。 除了RDRRC持续的支持外，2016年，医学院院长资助了四个2000万美元 转型研究计划仿照P30机制，以支持校园内的核心设施。 因此，强大的基础设施已经到位，可以在此基础上在RDRRC内建立新的创新核心，并 还通过试点资金将其利用与已建立的核心相结合。执行委员会， 由中心主任和副主任、研究资源核心领导和 更多具有丰富核心活动经验的CU教职员工将不断审查、确定优先顺序和 适当地定向对RDRRC核心访问的请求。整体的科学领导地位是由 成立一个咨询委员会，由公认的CU内部专家和外部专家组成，由华金博士担任主席 埃斯皮诺萨，琳达肾病唐氏综合症中心执行主任，国际公认的 专家利用数据丰富的管道方法探索21三体并发症的免疫基础。 有许多独特的资源集中在粘膜在人类疾病发病机制中的作用，CU RDRRC将是一项国家资源，这一点得到了多封外部支持信的确认。CU SOM院长 而医学部也将为试点拨款提供资金支持，以促进这一项目的成功 RDRRC。总体而言，行政核心的任务是促进风湿病领域的研究， 特别强调早期职业发展和改进疾病治疗和预防。

The Administrative Core will support the 43 members of the University of Colorado (CU) NIAMS P30 Rheumatic Disease Research Resource Center (RDRRC) in all aspects of study implementation, management, execution, regulatory compliance and reporting. The overall goal of this Administrative Core is to enhance and expand the research base by providing members a direct line for Center communication, organized access to Research Resource Core consultation and member discounts, and participation in all of the Programs outlined in the proposal. Dr. Michael Holers will serve as the Administrative Core Director, and Dr. Kristi Kuhn will serve the function of Associate Director. The Center Administrator, Ms. Lindsay McBride, will manage the fiscal aspects, and Ms. Becky Alberti-Powell will serve as the conduit for communication and outreach. The Enrichment Program will be headed up by Dr. Holers, with a focus throughout on early career development. As part of this, a Pilot and Feasibility Grants Program will be overseen by Dr. Robert Fuhlbrigge, Dr. Kristi Kuhn will integrate a Specific Aims and Grants Pre-Submission Review Program into the existing strong CU CTSA-supported program, and as well a Visiting Professor and Novel Technologies Review Series will be organized and managed. Dr. Kevin Deane will lead the Social Media and Communications Program. An innovative Patient Impact Program, including both Biomarker and Therapeutic Development components that will be integrated with the CU Innovations Center, will be co-directed by Dr. Holers and Dr. Ashley Frazer-Abel. In addition to ongoing RDRRC support, in 2016 the Dean of the School of Medicine (SOM) funded four $20M Transformational Research programs modeled on the P30 mechanism to bolster core facilities on the campus. As a result, a strong infrastructure is in place upon which to build new innovative cores within this RDRRC and also integrate through pilot funding their utilization with already established cores. The Executive Committee, consisting of the Center Director and Associate Director, the Research Resource Core leadership and additional CU faculty members with extensive core activities experience, will continually review, prioritize and appropriately direct requests for RDRRC Core access. The overall scientific leadership is bolstered by incorporation of an Advisory Committee of recognized internal CU and external experts chaired by Dr. Joaquin Espinosa, Executive Director of the Linda Crnic Down Syndrome Center and an internationally recognized expert in the use of data rich pipeline methods to explore the immune basis for complications of trisomy 21. With many unique resources focused on the role of the mucosa in the pathogenesis of human disease, the CU RDRRC will be a national resource, as confirmed by multiple external letters of support. The CU SOM Dean and Department of Medicine will also provide financial support for pilot grants to enhance the success of this RDRRC. Overall, the mission of the Administrative Core to promote research in the area of rheumatic disease, with a special emphasis on early career development and improving disease treatment and prevention.